Announcements Trials
Browse Landscape

Status

Approved for marketing 2No longer available 1

Sponsor Class

OTHER 4INDUSTRY 3

Study Type

Interventional 115Observational 26Expanded_access 3

Sponsor

Cancer Type

Thoracic 47Gastrointestinal 38Lymphoid 37Other hematologic neoplasm 36Genitourinary 28CNS 28Plasma cell 27Dermatologic 26Breast 25Sarcoma 22Tumor-Agnostic 16Myeloid 14Other solid neoplasm 10Gynecologic 10Head & Neck 9Endocrine 6NET 3

Conditions

Neuroendocrine Tumors 3

Interventions

surufatinib 1lutetium Lu 177 dotatate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Expanded_access × NET × Clear all
NCT04814732 2024-04-12

Expanded Access Program of Surufatinib

Hutchmed

No longer available
EndocrineNET

Neuroendocrine Tumors

NCT04334837 2020-10-09

Copper Cu 64 Dotatate for the Detection, Localization and Monitoring of SSTR Expressing (NETs)

Curium US LLC

Approved for marketing
EndocrineNET

Neuroendocrine Tumors

NCT02705313 2018-04-09

EAP 177Lu-DOTA0-Tyr3-Octreotate for Inoperable, SSR+, NETs, Progressive Under SSA Tx

Advanced Accelerator Applications

Approved for marketing
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡